Pharmaceutical-themed funds picked up, with some funds rising by more than 16%!

With the more scientific and rational medical insurance centralized procurement policy, and the recent performance of leading enterprises exceeding expectations, market sentiment has gradually eased, and the market of the pharmaceutical sector has rebounded sharply, driving the recovery of pharmaceutical theme funds
.
According to Wind data, from October 12 to October 19, a total of 76 pharmaceutical-themed funds in the market, including actively managed and passively managed, rose by more than 10%, and some of them even rose by more than 16%.

Specifically, from October 12 to October 19, Yongying Pharmaceutical Health A led with a 16.
80% increase
.
It is understood that the fund was established on May 20, 2020, and the performance comparison benchmark is the yield of the China Securities Medicine and Health Index ×80% + the yield of the China Bond-Composite Index (full price) ×20%.

The fund has returned 11.
14% since its inception, -10.
85% so far this year, 16.
49% in the past month and 0.
97%
in the past year.
For nearly a year, the fund ranked 68/2317
in its class.
Wells Fargo Biomedical Technology A followed closely behind, rising 12.
55%
between October 12 and October 19.
Founded on March 12, 2019, the benchmark for performance comparison is the yield of the CSI Healthcare Index of × 40% + the yield of the Hang Seng Healthcare Index (adjusted for exchange rates) × 40% + the yield of the CSI All Bonds Index ×20%.

Since its inception, the fund has returned 75.
68%, -21.
50% this year, 4.
55% in the past January, -27.
30% in the past one year, and 46.
64%
in the past three years.
In the past year, the fund has ranked 5115/5547
in its class.
The analysis believes that the recent strong rise in the pharmaceutical sector is mainly catalyzed by the moderate policy, and the valuation of the pharmaceutical sector is relatively low this year, while the performance growth rate of most pharmaceutical companies has recovered or even grown slowly, and many sub-industries are still maintaining high-speed performance growth, and the fundamentals of the pharmaceutical industry itself are healthy and strong
.
Looking ahead, many fund managers expressed their optimism about the two directions of
innovative drugs and domestic medical equipment.
In terms of innovative drugs, with the continuous emergence of a new generation of innovative drug products represented by ADC and oligonucleotide drugs, the innovative drug industry is booming, and some of them have begun to contribute revenue and profits to enterprises, and have broad prospects
in the future.
In terms of medical equipment, with the advancement of new medical infrastructure, the medical equipment industry has a high prosperity, and the trend of domestic substitution is strengthened, which will effectively increase the number of domestic overall medical resources, and the medical equipment industry may usher in an upward cycle
of two to three years.
Guohai Securities also believes that as far as the future market is concerned, the long-term value of the pharmaceutical sector may usher in a return
.
In the direction of segmentation, the landing of innovative drug achievements, the concentration of medical device market share to the leader, and the release of lagging demand for medical services are expected to bring certain market opportunities
.
In addition, companies related to innovative drugs (including CXOs) are also worth watching
.
CXO is a variety of outsourcing services for pharmaceutical companies from new drug research and development to production, thereby reducing costs and creating greater benefits, from the fundamental logic of CXO, it is still a general trend to continuously undertake global related capacity transfer under the improvement of China's manufacturing capacity; From the perspective of performance, the CXO represented by WuXi AppTec maintained rapid growth, the industry fundamentals were long-term good, and the short-term valuation adjustment was sufficient
.
In fact, from the perspective of the top ten heavy stocks of pharmaceutical funds, there are also many CXO head companies such as WuXi AppTec, Kanglong Chemical, WuXi Biologics, and ProPharmaceutical, which shows that the fund is optimistic
about the CXO sector.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.